The Torrent Group, a diversified conglomerate, surpassed $20 billion (Rs 1.68 lakh crore) in market capitalization on Friday. This represents nearly a doubling of its market value, driven by robust growth across businesses, ranging from pharmaceuticals to energy.

 Torrent Group's m-cap stood at $10.8 billion (Rs 90,230 crore) on June 6, 2023.

On Friday, two listed companies of the group, Torrent Pharmaceuticals Limited and Torrent Power Limited gained 2.22 per cent and 2.59 per cent, respectively, setting a new milestone for the group's market capitalisation at $20.2 billion at the close of market hours, according to stock exchange data.

Steady growth in the group's market capitalisation mirrors robust financial performance, sustained growth trajectory and business expansions across verticals.At the core of its growth strategy is the business model driven by acquisitions.The group has already implemented a succession plan where the third generation of the founder late UN Mehta has assumed all prominent driving seats across businesses.Torrent Pharma has been an early mover into acquisitions when it acquired Elder Pharma in 2013, followed by a spree of acquisitions with latest being Curatio in 2022 to foray into the dermatology segment. The company's large and bold bets are paying off a decade later.Recently, the company inked a pact with Takeda Pharmaceuticals to commercialise its novel gastrointestinal drug Vonoprazan in India under the Torrent brand name of Kabvie for treatment of acid related disorders - Gastroesophageal Reflux Disease (GERD).Torrent Pharma reported a 33 per cent jump in the net profit at Rs 1,656 crore for the fiscal 2023-24 with a revenue growth of over 12 per cent at Rs 10,728 crore. The company earns about 50 per cent of its revenues from the domestic market.During the past year, Torrent Pharma's India business grew by 10 per cent, while on a MAT (moving annual turnover) basis, the company has outperformed the market across all focus therapies aided by strong new launch performance.Torrent Pharma has 20 brands in the top 500 brands in the Indian Pharmaceuticals Market (IPM), with 17 brands worth more than Rs 100 crore.Ranked 5th in the Indian Pharmaceuticals Market, Torrent is amongst the top 5 in the therapeutics segments of Cardiovascular (CV), Gastrointestinal (GI), Central Nervous System (CNS), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The company has a presence in 50 countries.The power arm of the group, Torrent Power reported a net profit of Rs 1,896 crore on the revenues of Rs 27,183 crore for fiscal 2023-24.The company has built 1,236 MW of renewable capacity with additional 3,041 MW capacities under development.It already has laid down a pipeline of projects in the renewable space.The company is investing in pumped-storage hydro (PSH) and the first project is likely to come up in the next five years.The company has also set ambitious plans for green hydrogen projects. The first pilot project on green hydrogen is being developed in Uttar Pradesh with the blending of green hydrogen with gas in the city gas distribution network in Gorakhpur.On the distribution front, Torrent Power distributes nearly 30 billion units to over 4.13 million customers across 12 cities.Read also: Torrent Pharmaceutical Gets CDSCO Panel Nod To Manufacture, Market Antidiabetic FDC

Santo Domingo – The Minister of Housing and Buildings (Mived), Carlos Bonilla, endorsed the US$190 million loan agreement between the Dominican Republic and the International Bank for Reconstruction and Development (IBRD) because he said it will be invested in health infrastructure.

According to the official, resources oriented to health are a requirement for the sustainable development of society.

He was invited by the Permanent Commission of Finance of the Chamber of Deputies as part of the process of socialization of the loan, pending approval. Before the Commission of legislators presided by Deputy José (Bertico) Santana, the Vice Minister of Mived, Ernesto Mejía, pointed out that they have already made the surveys of the places that require hospital constructions and first level primary care centers that require renovation.

GAINESVILLE, Fla. — En un granero al aire libre en el borde de la Universidad de Florida, el veterinario Juan Campos Krauer examina las pezuñas y las orejas de un armadillo muerto en busca de signos de infección.

Sus garras están apretadas y cubiertas de sangre. Campos Krauer cree que lo golpearon en la cabeza mientras cruzaba una carretera cercana.

Luego, corta con un bisturí la parte inferior del animal y extrae todos los órganos importantes: corazón, hígado, riñones. Coloca las muestras embotelladas en un congelador ultra frío, en su laboratorio de la universidad.

Campos Krauer planea examinar el armadillo para detectar lepra, un antiguo mal también conocido como enfermedad de Hansen que puede provocar daño a los nervios y desfiguración en humanos. Junto con otros científicos están tratando de resolver un misterio médico: por qué Florida central se ha convertido en una zona crítica para las antiguas bacterias que la causan.

La lepra sigue siendo rara en Estados Unidos. Pero Florida, que a menudo informa el mayor número de casos de cualquier estado, ha visto un aumento en pacientes. El epicentro está al este de Orlando. El condado de Brevard informó un asombroso 13% de los 159 casos de lepra del país en 2020, según un análisis del Tampa Bay Times de datos estatales y federales.

Muchas preguntas sobre el fenómeno siguen sin respuesta. Pero expertos en lepra creen que los armadillos juegan un papel en la propagación de la enfermedad a las personas. Para comprender mejor quién está en riesgo y prevenir infecciones, unos 10 científicos se unieron el año pasado para investigar.

El grupo incluye investigadores de la Universidad de Florida, la Universidad Estatal de Colorado y la Universidad de Emory, en Atlanta.

“Realmente no sabemos cómo está ocurriendo esta transmisión”, dijo Ramanuj Lahiri, jefe de la rama de investigación de laboratorio del Programa Nacional de Enfermedad de Hansen, que estudia las bacterias involucradas y cuida a los pacientes con lepra en todo el país.

“Nada encajaba”

Se cree que la lepra es la infección humana más antigua de la historia. Probablemente ha estado enfermando a las personas durante al menos 100,000 años. Es fuertemente estigmatizada: en la Biblia, se describía como un castigo por pecar. En tiempos más modernos, los pacientes eran aislados en “colonias” alrededor del mundo, incluyendo en Hawaii y Louisiana.

En casos leves, las bacterias de crecimiento lento causan algunas lesiones. Si no se trata, pueden paralizar las manos y los pies.

Pero en realidad es difícil enfermarse de lepra, ya que la infección no es muy contagiosa. Los antibióticos pueden curar la enfermedad en uno o dos años. Están disponibles de forma gratuita a través del gobierno federal y de la Organización Mundial de la Salud (OMS), que lanzó una campaña en la década de 1990 para eliminar la lepra como problema de salud pública.

En 2000, los casos reportados en EE.UU. cayeron a su nivel más bajo en décadas, con 77 infecciones. Pero luego aumentaron, promediando alrededor de 180 por año desde 2011 hasta 2020, según datos del Programa Nacional de Enfermedad de Hansen.

Durante ese tiempo, surgió una tendencia curiosa en Florida.

En la primera década del siglo XXI, el estado registró 67 casos. El condado de Miami-Dade tuvo 20 infecciones, la mayoría de cualquier condado de Florida. La gran mayoría de esos casos fueron adquiridos fuera del país, según un análisis del Times de datos del Departamento de Salud de Florida.

Pero durante los siguientes 10 años, los casos registrados en el estado fueron más del doble, 176, y el condado de Brevard tomó el protagonismo.

El condado, cuya población es aproximadamente una quinta parte del tamaño de Miami-Dade, registró 85 infecciones durante ese tiempo, con mucho, la mayoría de cualquier condado en el estado y casi la mitad de todos los casos de Florida. En la década anterior, Brevard solo registró cinco casos.

De manera notable, al menos una cuarta parte de las infecciones de Brevard fueron adquiridas dentro del estado, no mientras los individuos estaban en el extranjero.

India, Brasil e Indonesia diagnostican más casos de lepra que en cualquier otro lugar, reportando más de 135,000 infecciones combinadas solo en 2022.

Las personas se estaban enfermando a pesar de no haber viajado a esas áreas ni haber estado en contacto cercano con pacientes con lepra, dijo Barry Inman, ex epidemiólogo del departamento de salud de Brevard que investigó los casos y se retiró en 2021.

“Nada encajaba”, dijo Inman. Algunos pacientes recordaron haber tocado armadillos, que se sabe que portan las bacterias. Pero la mayoría no, dijo. Muchos pasaron mucho tiempo al aire libre, incluidos trabajadores de jardines y ávidos jardineros. Los casos eran generalmente leves.

Era difícil determinar dónde contrajeron la enfermedad, agregó. Debido a que las bacterias crecen tan lentamente, pueden pasar entre nueve meses y 20 años para que comiencen los síntomas.

¿Amoeba o insectos culpables?

Concientizar sobre la lepra podría desempeñar un papel en el aumento de casos en Brevard. Los médicos deben reportar la lepra al Departamento de Salud. Sin embargo, Inman dijo que muchos en el condado no lo sabían, por lo que trató de educarlos después de notar los casos a fines de la década de 2000.

Pero ese no es el único factor en juego, dijo Inman. “No creo que haya ninguna duda en mi mente de que está ocurriendo algo nuevo”, dijo.

Otras partes en el centro de Florida también han registrado más infecciones. De 2011 a 2020, el condado de Polk registró 12 casos, triplicando su número en comparación con los 10 años anteriores. El condado de Volusia registró 10 casos. No reportó ninguno en la década anterior.

Los científicos se están enfocando en los armadillos. Sospechan que estos animales que son cavadores pueden causar indirectamente infecciones a través de la contaminación del suelo.

Los armadillos, que están protegidos por caparazones duros, sirven como buenos huéspedes para las bacterias, a las que no les gusta el calor y pueden prosperar en los animales cuyos rangos de temperatura corporal son de 86 a 95 grados Fahrenheit.

Los colonos probablemente trajeron la enfermedad al Nuevo Mundo hace cientos de años, y de alguna manera los armadillos se infectaron, dijo Lahiri, el científico del Programa Nacional de Enfermedad de Hansen.

Estos mamíferos nocturnos pueden desarrollar lesiones por la enfermedad igual que los humanos. Hay más de un millón de armadillos en Florida, estimó Campos Krauer, profesor asistente en el Departamento de Ciencias Clínicas de Animales Grandes de la Universidad de Florida.

Cuántos portan lepra no está claro. Un estudio publicado en 2015 con más de 600 armadillos en Alabama, Florida, Georgia y Mississippi encontró que aproximadamente el 16% mostraban evidencia de infección. Expertos en salud pública creen que la lepra anteriormente estaba confinada a los armadillos al oeste del río Mississippi y luego se extendió hacia el este.

Manipular los animales es un peligro conocido. La investigación de laboratorio muestra que las amebas unicelulares, que viven en el suelo, también pueden portar las bacterias.

Los armadillos aman desenterrar y comer lombrices, lo que frustra a los propietarios de viviendas cuyos jardines dañan. Los animales pueden eliminar las bacterias mientras buscan comida, pasándolas a las amebas, que podrían infectar a las personas más tarde.

Los expertos en lepra también se preguntan si los insectos ayudan a propagar la enfermedad. Las garrapatas que chupan sangre también podrían ser culpables, según muestra la investigación de laboratorio.

“Algunas personas que están infectadas tienen poca o ninguna exposición al armadillo”, dijo Norman Beatty, profesor asistente de medicina en la Universidad de Florida. “Probablemente hay otra fuente de transmisión en el medio ambiente”.

Campos Krauer, que ha estado buscando armadillos muertos en las calles de Gainesville, quiere reunir animales infectados y dejarlos descomponer en un área cercada, permitiendo que los restos se empapen en una bandeja con tierra mientras las moscas ponen huevos. Espera examinar la tierra y las larvas para ver si recogen las bacterias.

Agregando intriga hay una cepa de lepra encontrada solo en Florida, según los científicos. En el estudio de 2015, los investigadores descubrieron que siete armadillos del Refugio Nacional de Vida Silvestre de Merritt Island, que está mayormente en Brevard pero cruza a Volusia, portaban una versión del patógeno no vista anteriormente.

Diez pacientes en la región también se vieron afectados por esta cepa. A nivel genético, es similar a otro tipo encontrado en armadillos en el país, dijo Charlotte Avanzi, investigadora de la Universidad Estatal de Colorado que se especializa en lepra. No se sabe si la cepa causa una enfermedad más grave, dijo Lahiri.

Reduciendo el riesgo

El público no debe entrar en pánico por la lepra, ni las personas deben apresurarse a sacrificar armadillos, advierten los investigadores.

Los científicos estiman que más del 95% de la población humana mundial tiene una capacidad natural para resistir la enfermedad. Creen que se necesitan meses de exposición a gotitas respiratorias para que ocurra la transmisión de persona a persona.

Pero cuando ocurren infecciones, pueden ser devastadoras. “Si lo entendemos mejor”, dijo Campos Krauer, “podremos aprender a vivir con él y reducir el riesgo”.

La nueva investigación también puede proporcionar información para otros estados del sur. Los armadillos, que no hibernan, se han estado moviendo hacia el norte, dijo Campos Krauer, alcanzando áreas como Indiana y Virginia.

Podrían ir más lejos debido al cambio climático.

Las personas preocupadas por la lepra pueden tomar precauciones simples, dicen los expertos médicos. Aquellos que trabajan en tierra deben usar guantes y lavarse las manos después. Elevar las camas de jardín o rodearlas con una cerca puede limitar las posibilidades de contaminación del suelo.

Si se desentierra una madriguera de armadillo, es mejor usar una mascarilla, dijo Campos Krauer. No jugar con los animales ni comerlos, agregó John Spencer, científico de la Universidad Estatal de Colorado que estudia la transmisión de la lepra en Brasil. Es legal cazarlos todo el año en Florida sin una licencia.

Hasta ahora, el equipo de Campos Krauer ha examinado 16 armadillos muertos encontrados en carreteras del área de Gainesville, a más de 100 millas del epicentro de la lepra del estado, tratando de obtener una idea preliminar de cuántos portan las bacterias.

Todavía ninguno ha dado positivo.

Este artículo fue producido por una asociación entre KFF Health News y el Tampa Bay Times.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

USE OUR CONTENT

This story can be republished for free (details).

Today, we’re sipping a hot cup of caffeinated black, while mulling the rise and fall and, apparently (!), rise again of Luckin Coffee, a chain whose cashless kiosks and discount lattes were once seen as China’s answer to Starbucks, before allegations emerged of widespread accounting fraud. This Bloomberg story has the best quote I’ve read all week, from a former executive (who was not accused of wrongdoing): “Obviously, it was wrong and unlawful to fabricate data. But you still have to acknowledge the great design that was its business model.” Anyway, here’s some news:

The FDA has questions about Eli Lilly’s experimental Alzheimer’s drug, STAT tells us. Documents released in advance of Monday’s advisory committee hearing show regulators are mulling whether donanemab, which slowed cognitive decline in a large study, should be limited to a subset of patients with a key biomarker, called tau, used to screen patients for Lilly’s trial. They also want to know if the drug’s benefits justify the risk of severe brain swelling and bleeds seen in the study.

The FDA took the rare step of publicly explaining why it rejected a drug, Endpoints relays. The agency put out a notice about the application to approve Vanda Pharmaceuticals’ sleep disorder drug Hetlioz as an insomnia medication, saying the company “does not provide substantial evidence of effectiveness” and didn’t show the drug was safe. It asked for a new “well-controlled” trial. Vanda is currently suing the FDA, while facing pressure to accept a takeover bid from Cycle Pharmaceuticals.

Continue to STAT+ to read the full story…

Santo Domingo.- In response to the alarming increase in dengue cases across the Americas in 2024, the Dominican Republic has strengthened its efforts to combat the disease with the support of the Pan American Health Organization (PAHO) and the World Health Organization (WHO).

So far this year, the region has reported over 8.6 million dengue cases, surpassing the 5.6 million reported in 2023. As of May 31, 2024, the Dominican Republic alone has recorded 7,574 cases.

With the onset of the peak dengue season, characterized by heat and rain that facilitate the spread of the mosquito vector, the Ministry of Public Health launched the National Plan for the Prevention and Control of Dengue on March 20. This plan, based on PAHO’s Integrated Management Strategy (EGI) for the prevention and control of arboviral diseases, aims to enhance early detection, clinical case management, intersectoral coordination, and integrated vector management. The plan also emphasizes communication and community participation to drive behavioral change in dengue prevention.

High-level political commitment has been crucial in preparing the country to tackle the dengue threat. This commitment is evident in the coordinated efforts of the ministries of Health and Education, local governments, academic institutions, specialized medical societies, and civil society representatives.

Vice President Raquel Peña has called on the Dominican people to join the fight against dengue by adhering to preventive measures in communities, schools, and workplaces.

Throughout 2024, PAHO/WHO, in collaboration with the National Health Service and universities, has supported the training of health professionals across different care levels. This includes training over 1,200 doctors from various provinces and more than 570 final-year medical and nursing students, thereby enhancing the diagnostic and clinical management capabilities for dengue.

“Quick and accurate decision-making in managing dengue patients is crucial to prevent progression to severe forms of the disease,” stated Dr. Victor Atallah, Minister of Public Health. “During an outbreak, preventing complications and deaths must be the top priority.”

Alba María Ropero Álvarez, PAHO/WHO representative in the Dominican Republic, emphasized the importance of communication and community participation campaigns to raise awareness about dengue prevention and early care seeking. “An informed population that eliminates mosquito breeding sites in their homes and stays informed through reliable sources is key to preventing dengue,” she said.

In a joint effort, the Ministry of Health and the Ministry of Education launched the “Anti-Dengue Family” strategy. This initiative promotes preventive habits through educational talks aimed at students, teachers, and community leaders, turning them into advocates within their communities. Students contribute 60 hours of community work, significantly bolstering preventive and health promotion efforts.

PAHO has also supported the creation and distribution of educational materials to health personnel in emergency rooms, outpatient clinics, and hospitals, including clinical management algorithms for dengue cases.

Furthermore, PAHO has backed vector control measures to reduce the population of Aedes aegypti mosquitoes, which transmit dengue, chikungunya, and Zika. This includes training entomologists, epidemiologists, and environmental health personnel, and organizing mosquito breeding site elimination campaigns.

“We recognize the Dominican Republic’s efforts to enhance surveillance, prevention, control, and clinical management of dengue, as well as its commitment to combatting the disease,” said Ropero Álvarez. “Maintaining these interventions and the involvement of all government and societal sectors is essential to effectively control dengue.”

he researchers wrote. Other drugs had similar levels of risk.“Current [PsA] treatment guidelines recommend targeted therapies when standard treatments (including non-steroidal

The Host

Julie Rovner
KFF Health News

@jrovner

Read Julie's stories.

Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A to Z,” now in its third edition.

It’s not surprising that the nursing home industry is filing lawsuits to block new Biden administration rules requiring minimum staffing at facilities that accept federal dollars. What is slightly surprising is the pushback against the rules from members of Congress. Lawmakers don’t appear to have the votes to disapprove the rule, but they might be able to force a floor vote, which could be embarrassing for the administration.

Meanwhile, Senate Democrats aim to force Republicans who proclaim support for contraceptive access to vote for a bill guaranteeing it, which all but a handful have refused to do.

This week’s panelists are Julie Rovner of KFF Health News, Rachel Cohrs Zhang of Stat, Alice Miranda Ollstein of Politico, and Sandhya Raman of CQ Roll Call.

Panelists

Rachel Cohrs Zhang
Stat News

@rachelcohrs

Read Rachel's stories.

Alice Miranda Ollstein
Politico

@AliceOllstein

Read Alice's stories.

Sandhya Raman
CQ Roll Call

@SandhyaWrites

Read Sandhya's stories.

Among the takeaways from this week’s episode:

• In suing to block the Biden administration’s staffing rules, the nursing home industry is arguing that the Centers for Medicare & Medicaid Services lacks the authority to implement the requirements and that the rules, if enforced, could force many facilities to downsize or close.
• Anthony Fauci, the retired director of the National Institute of Allergy and Infectious Diseases and the man who advised both Presidents Donald Trump and Joe Biden on the covid-19 pandemic, testified this week before the congressional committee charged with reviewing the government’s pandemic response. Fauci, the subject of many conspiracy theories, pushed back hard, particularly on the charge that he covered up evidence that the pandemic began because dangerous microbes escaped from a lab in China partly funded by the National Institutes of Health.
• A giant inflatable intrauterine device was positioned near Union Station in Washington, D.C., marking what seemed to be “Contraceptive Week” on Capitol Hill. Republican senators blocked an effort by Senate Majority Leader Chuck Schumer to force a vote on consideration of legislation to codify the federal right to contraception. Immediately after, Schumer announced a vote for next week on codifying access to in vitro fertilization services.
• Hospitals in London appear to be the latest, high-profile cyberattack victims, raising the question of whether it might be time for some sort of international cybercrime-fighting agency. In the United States, health systems and government officials are still in the very early stages of tackling the problem, and it is not clear whether Congress or the administration will take the lead.
• An FDA advisory panel this week recommended against the formal approval of MDMA, a psychedelic also known as ecstasy, to treat post-traumatic stress disorder. Members of the panel said there was not enough evidence to recommend its use. But the discussion did provide more guidance about what companies need to present in terms of trials and evidence to make their argument for approval more feasible.

Also this week, Rovner interviews KFF Health News’ Bram Sable-Smith, who reported and wrote the latest KFF Health News-NPR “Bill of the Month” feature about a free cruise that turned out to be anything but. If you have an outrageous or baffling bill you’d like to send us, you can do that here.

Plus, for “extra credit,” the panelists suggest health policy stories they read this week that they think you should read, too:

• Julie Rovner: Abortion, Every Day’s “EXCLUSIVE: Health Data Breach at America’s Largest Crisis Pregnancy Org,” by Jessica Valenti.
• Alice Miranda Ollstein: The Washington Post’s “Conservative Attacks on Birth Control Could Threaten Access,” by Lauren Weber.
• Rachel Cohrs Zhang: ProPublica’s “This Mississippi Hospital Transfers Some Patients to Jail to Await Mental Health Treatment,” by Isabelle Taft, Mississippi Today.
• Sandhya Raman: Air Mail’s “Roanoke’s Requiem,” by Clara Molot.

Click to open the transcript

Transcript: Nursing Home Staffing Rules Prompt Pushback

[Editor’s note: This transcript was generated using both transcription software and a human’s light touch. It has been edited for style and clarity.] 

Mila Atmos: The future of America is in your hands. This is not a movie trailer, and it’s not a political ad, but it is a call to action. I’m Mila Atmos, and I’m passionate about unlocking the power of everyday citizens. On our podcast, Future Hindsight, we take big ideas about civic life and democracy and turn them into action items for you and me. Every Thursday we talk to bold activists and civic innovators to help you understand your power and your power to change the status quo. Find us at futurehindsight.com or wherever you listen to podcasts.

Julie Rovner: Hello, and welcome back to “What the Health?” I’m Julie Rovner, chief Washington correspondent for KFF Health News, and I’m joined by some of the best and smartest health reporters in Washington. We’re taping this week on Thursday, June 6, at 10 a.m. As always, news happens fast and things might have changed by the time you hear this. So here we go. We are joined today via video conference by Alice Miranda Ollstein of Politico.

Alice Miranda Ollstein: Hello.

Rovner: Sandhya Raman of CQ Roll Call.

Sandhya Raman: Good morning.

Rovner: And Rachel Cohrs Zhang of Stat News.

Rachel Cohrs Zhang: Hi, everybody.

Rovner: Later in this episode, we’ll have my interview with KFF Health News’ Bram Sable-Smith, who reported and wrote this month’s KFF Health News/NPR “Bill of the Month.” It’s about a free cruise that turned out to be anything but. But first, this week’s news. We’re going to start this week with those controversial nursing home staffing rules.

In case you’ve forgotten, back in May, the Biden administration finalized rules that would require nursing homes that receive federal funding, which is basically all of them, to have nurses on duty 24/7/365, as well as impose other minimum staffing requirements.

The nursing home industry, which has been fighting this effort literally for decades, is doing what most big powerful health industry players do when an administration does something it doesn’t like: filing lawsuits. So what is their problem with the requirement to have sufficient staff to care for patients who, by definition, can’t care for themselves or they wouldn’t be in nursing homes?

Cohrs Zhang: Well, I think the groups are arguing that CMS [Centers for Medicare & Medicaid Service] doesn’t have authority to implement these rules, and that if Congress had wanted these minimum staffing requirements, Congress should have done that and they didn’t. So they’re arguing that they’re overstepping their boundaries, and we are seeing this lawsuit again in Texas, which is a popular venue for the health care industry to try to challenge rules or legislation that they don’t like.

So, I think it isn’t a surprise that we would see these groups sue, given the financial issues at stake, given the fearmongering about facilities having to close, and just the hiring that could have to happen for a lot of these facilities. So it’s not necessarily a surprise, but it will certainly be interesting and impactful for facilities and for seniors across the nation as this plays out.

Rovner: I mean, basically one of their arguments is that there just aren’t enough people to hire, that they can’t get the number of people that they would need, and that seems to be actually pretty persuasive argument at some point, right?

Cohrs Zhang: I mean, there is controversy about why staffing shortages happen. Certainly there could be issues with the pipeline or with nursing schools, education. But I think there are also arguments that unions or workers’ rights groups would make that maybe if facilities paid better, then they would get more people to work for them. Or that people might exit the industry because of working conditions, because of understaffing, and just that makes it harder on the workers who are actually there if their workloads are too much. Or they’re expected to do more work — longer hours or overtime — or their vacation is limited, that kind of thing.

So I think it is a surprisingly controversial issue that doesn’t have an easy answer, but that’s the perspectives that we’re seeing here.

Rovner: I mean, layering onto this, it’s not just the industry versus the administration. Now Congress is getting into the act, which you rarely see. They’re talking about using the Congressional Review Act, which is something that Congress can do. But of course, when you’re in the middle of an administration that’s done it, it would get vetoed by the president. So they can’t probably do anything. Sandhya, I see you nodding your head. These members of Congress just want to make a statement here?

Raman: Yeah. So Sen. James Lankford insured the resolution earlier this week to block the rule’s implementation, and it’s mostly Republicans that have signed on, but we also have [Sen.] Joe Manchin and [Sen.] Jon Tester. But the way it stands, it doesn’t have enough folks on board yet, and it would also need to be taken up. It faces an uphill climb like many of these things.

Rovner: Somebody actually asked me yesterday though, can they do this? And the answer is yes, there is the Congressional Review Act. Yes, Congress with just a majority vote and no filibuster in the Senate can overturn an administration rule. But like I said, it usually happens when an administration changes its hands because it does have to be signed by the president and the president can veto it.

If the president vetoes it, then they would need a veto override majority, which they clearly don’t seem to have in this case. But obviously there is enough concern about this issue. I think there’s been a Congressional Review Act resolution introduced in the House too, right?

Ollstein: It’s really tough because, like Rachel said, these jobs are low-paid. They’re emotionally and physically grueling. It’s really hard to find people willing to do this work. And at the same time, the current situation seems really untenable for patients. There’s been so many reports of really horrible patient safety and hygiene issues and all kinds of stuff in part, not entirely the fault of understaffing, but not helped by understaffing certainly.

I think, like, we see on so many fronts in health care, there are attempts to do something about this situation that has become untenable, but any attempt also will piss off someone and be challenged.

Rovner: Yeah, absolutely. And we should point out that nursing homes are staffed primarily not by nurses, but by nurses aides of various training levels. So this is not entirely about a nursing shortage, it is about a shortage of workers who want to do this, as you say, very grueling and usually underpaid work.

Well, speaking of controversial things, Dr. Tony Fauci, the now-retired head of the NIH’s National Institute of Allergy and Infectious Diseases, and currently the man most conspiracy theorists hold responsible for the entire covid-19 pandemic, testified before the House Select Committee on the pandemic Monday. And not surprisingly, sparks flew. What, if anything, did we learn from this hearing?

Cohrs Zhang: The interesting part of this hearing was watching how Dr. Fauci positioned himself in response to a lot of these criticisms that have been circulating. The committee has been going through different witnesses, and specifically it criticized one of his deputies, essentially, who had some unflattering emails released showing that he appeared to be trying to delete emails or use personal accounts to avoid public records requests from journalists or other organizations …

Rovner: I’m shocked, shocked that officials would want to keep their information away from prying reporters’ eyes.

Cohrs Zhang: It’s not surprising, but it is surprising to see it in writing. But this is, again, everyone is working from home and channels of communication were changing. But I think we did see Dr. Fauci pretty aggressively distancing himself, downplaying the relationship he had with this individual and saying that they worked on research together, but he wasn’t necessarily advising agency policy.

So that’s at least how he was framing the relationship. So he definitely downplayed that. And I think an interesting comment he made — I’m curious to see what you think about this, Julie — was that he didn’t say that the lab leak theory itself was a conspiracy, but his involvement and a cover-up was a conspiracy. And so it did seem that some of the rhetoric has at least changed. He seemed more open-minded, I guess, to a lab leak theory than I expected.

Rovner: I thought he was pretty careful about that. I think it was the last thing he said, which is that we’re never really going to know. I mean, it could have been a lab leak. It could have happened. It could have been an animal from the wet market. The Chinese have not been very forthcoming with information. I personally keep wondering why we keep pounding at this.

I mean, it seems unlikely that it was a lab leak and then a conspiracy to cover it up. It clearly was one or the other, and there’s a lot of differences of opinions. And that was the last thing he said is that it could have been either. We don’t know. That’s always struck me as the, “OK, let’s talk about something else.” Anyway, let’s talk about something else.

Raman: I was just going to add, we did see a personal side to him, which I think we didn’t see as much when he was in his official role when he was talking. It was about the death threats that he and his family have been receiving when responding to a lot of the misinformation going around about that. And I thought that was striking compared to, just juxtaposed, with a lot of the other [indecipherable] with [Rep.] Marjorie Taylor Greene saying, “Oh, you’re not a real doctor.” There’s a lot of colorful protesters. And I just thought that stood out, too.

Rovner: Yeah, he did obviously, I think, relish the chance to defend himself from a lot of the charges that have been leveled at him. And I think … his wife is a prominent scientist in her own right — obviously can take care of herself — but I think he was particularly angry that there had been death threats leveled toward his grown daughters, which probably a bit out of line. Alice, you wanted to add something.

Ollstein: Yeah, I think it’s also been interesting to see the shift among Democrats on the committee over time. I think they’ve gone from an attitude of Republicans are on a total witch hunt, this is completely political, this is muddying the waters and fueling conspiracy theories and will lead to worse public health outcomes. And I think based on some of the revelations, like Rachel said about emails and such, they have come to a position of, oh, there might be some things that need investigating and need accountability in here.

But I think their frustration seems to be what it’s always been in that how will this lead to making the country better prepared in the future for the next pandemic — which may or may not already be circulating, but certainly is inevitable at some point. Either way, it’s all well and good to hold officials accountable for things they may have done, but how does that lead to making the country more prepared, improving pandemic response in the future? That’s what they feel is the missing piece here.

Rovner: Yeah. I think there was not a lot of that at this hearing, although I feel like they had to go through this maybe to get over to the other side and start thinking about what we can do in the future to avoid similar kinds of problems. And obviously you get a disease that you have no idea what to do about, and people try to muddle through the best they can. All right, now we are going to move on and we’ll talk about abortion where there is always lots of news.

Here in Washington, there is a giant inflatable IUD flying over Union Station Wednesday to highlight what seems to be Contraception Week on Capitol Hill. Not coincidentally, it’s also the anniversary this week of the Supreme Court’s 1965 ruling Griswold v. Connecticut that created the right to birth control. Alice, what are Democrats, particularly in the Senate where they’re in charge, doing to try to highlight these potential threats to contraceptive access?

Ollstein: So this vote that happened that was blocked because only two Republicans crossed the aisle to support this Right to Contraception bill — it’s the two you expect, it’s [Sen.] Lisa Murkowski and [Sen.] Susan Collins — and you’re already seeing Democrats really make hay of this. Both Democrats and their campaign arms and outside allied groups are planning to just absolutely blitz this in ads. They’re holding events in swing states related to it, and they’re going hard against individual Republicans for their votes.

I think the Republicans I talked to who voted no, they had a funny mixed message about why they were voting no on it. They were both saying that the bill was this sinister Trojan horse for forcing religious groups to promote contraception and even abortion and also gender-affirming care somehow. But also, the bill was a pointless stunt that wouldn’t really do anything because there is no threat to contraception. But also Republicans have their own rival bill to promote access to contraception.

So access to contraception isn’t a problem, but please support my bill to improve access to contraception. It’s a tough message. Whereas Democrats’ message is a lot simpler. You can argue with it on the merits, but it’s a lot simpler. They point to the fact that Supreme Court Justice Clarence Thomas has expressed interest and actually called on the court to revisit precedents that protect the right to contraception.

Lots of states have thwarted attempts to enact protections for contraception. And a lot of anti-abortion groups have really made a big push to muddy the waters on medical understanding of what is contraception versus what is abortion, which we can get into later.

Rovner: Yes, which we will. Sandhya, did you want to add something?

Raman: Yeah, and I think that something that I would add to what Alice was saying is just how this is kind of at the same time a little bit different for the Democrats. Something that I wrote about this week was just that after the Dobbs [v. Jackson Women’s Health Organization] decision, we had the then-Democratic House vote on several different bills, but the Democrats have not really been holding this chamber-wide vote on bills related to abortion, contraception for the most part. And so this was the first time that they are stepping into that.

They’ve done the unanimous consent requests on a lot of these bills. And even just a couple months ago when talks are really heating up on IVF, there’s other things that we have to get to, appropriations and things like that, and this would just get bogged down. And they were shying away from taking floor time to do this. So I think that was an interesting move that they’re doing this now and that they’re going to vote on an IVF next week and whatever else next down the line.

Rovner: Yeah, I noticed that as soon as this bill went down, Sen. [Chuck] Schumer teed up the Right to IVF bill for a vote next week. But Alice, as you were alluding to, I mean, where this gets really uncomfortable for Republicans is that fine line between contraception and abortion. Our colleague Lauren Weber has a story about this this week [“Conservative Attacks on Birth Control Could Threaten Access,”], which is your extra credit, so why don’t you tell us about it?

Ollstein: Yeah. So she did a really great job highlighting how, especially at the state level where a lot of these battles are playing out, anti-abortion groups that are very influential are making arguments that certain forms of birth control are abortifacients. This is completely disputed by medical experts and the FDA [Food and Drug Administration] that regulates these products. They say, just to be clear about what we’re talking about, we’re talking about some forms of emergency contraception, which is taken after sex to prevent pregnancy. It is not an abortifacient. It won’t work if you’re already pregnant. It prevents pregnancy. It does not terminate a pregnancy. They are also saying this about some IUDs, intrauterine devices, and even about some hormonal birth control pills.

So there’s been pushback that Lauren detailed in her story, including from some Republicans who are trying to correct the record. But this misinformation is getting really entrenched, and I think it’s something we should all be paying attention to when it crops up, especially in the mouths of people in power.

Rovner: I mean, when I first started writing about it it was not entirely clear. There was thought that one of the ways the morning-after pill worked was by preventing implantation of a fertilized egg, which some people consider, if you consider that fertilization and not implantation, is the beginning of life. According to doctors, implantation is the beginning of pregnancy, among other things, because that’s when you can test for it.

But those who believe that fertilization is the beginning of life — and therefore something that prevents implantation is an abortion — were concerned that IUDs, and mostly progesterone-based birth control that prevented implantation, were abortifacients. Except that in the years since, it’s been shown that that’s not the case.

Ollstein: Right.

Rovner: That in fact, both IUDs and the morning-after pill work by preventing ovulation. There is no fertilized egg because there’s no egg. So they are not abortifacients. On the other hand, the FDA changed the labeling on the morning-after pill because of this. And yet the Hobby Lobby case [Burwell v. Hobby Lobby Stores Inc.] that the decision was written by Justice [Samuel] Alito, basically took that premise, that they were allowed to not offer these forms of contraception because they believed that they were acted as abortifacients, even though science suggests that they didn’t. It’s not something new, and it’s not something I don’t think is going to go away anytime in the near future.

Raman: I would add that it also came up in this week’s Senate Health [Committee] hearing, that line of questioning about whether or not different parts of birth control were abortifacients. Sen. [Patty] Murray did that line of questioning with Dr. Christina Francis, who’s the head of the anti-abortion obstetrician-gynecology group and went through on Plan B, IUDs and different things. And there was a back and forth of evading questions, but she did call IUDs as abortifacients, which goes back to the same thing that we’re saying.

Rovner: Right, which they have done all along.

Ollstein: Yeah. I mean, I think this really spotlights a challenge here, which is that Republicans’ response to votes like this week and things that are playing out in the state level, they’re scoffing and saying, “It’s absolutely ridiculous to suggest that Republicans are trying to ban birth control. This is completely a political concoction by Democrats to scare people into voting for them in November.”

What we’re talking about here are not bans on birth control, but there are policies that have been introduced at both the state and federal level that would make birth control, especially certain forms like we were just talking about, way harder to access. So there are proposals to carve them out of Obamacare’s contraception mandate, so they’re not covered by insurance.

That’s not a ban. You can still go pay out-of-pocket, but I remember all the people who were paying out-of-pocket for IUDs before Obamacare: hundreds and hundreds of dollars for something that is now completely free. And so what we’re seeing right now are not bans, but I think it’s important to think about the ways it would still restrict access for a lot of people.

Rovner: Before we leave the nation’s capital it seems that the Supreme Court’s upcoming decision on the abortion pill may not be the last word on the case. While it seemed likely from the oral arguments that the justices will agree that the Texas doctors who brought the case don’t have standing, there were three state attorneys general who sought to become part of the case when it was first considered back in Texas. So it would go back to Judge [Matthew] Kacsmaryk, our original judge who said that the entire abortion pill approval should be overturned. It feels like this is not the end of fighting about the abortion pill’s approval at the federal level. I mean, I assume that that’s something that the drug industry, among others, won’t be happy about.

Ollstein: Courts could find that the states don’t have standing either, that this policy does not harm them in any real way. In fact, Democratic attorneys general have argued the exact opposite, that the availability of mifepristone helps states: saves a lot of money; it prevents pregnancy; it treats people’s medical needs. So obviously, Kacsmaryk has a very long anti-abortion record and has sided with these challenges in a lot of cases. But that doesn’t mean that this would necessarily go anywhere.

But your bigger point that the Supreme Court’s upcoming ruling on mifepristone is not the end, it certainly is not. There’s going to be a lot more court challenges, some already in motion. There’s going to be state-level policy fights. There’s going to be federal-level policy fights. If Trump is elected, groups want him to do a lot of things through executive order to restrict mifepristone or remove it from the market entirely through the FDA. So yes, this is not going to be over for the foreseeable future.

Rovner: Well, meanwhile, in a case that might be over for the foreseeable future, the Texas Supreme Court last week officially rejected the case brought by 20 women who nearly died when they were unable to get timely care for pregnancy complications. The justices said in their ruling that while the women definitely did suffer, the fault lay with the doctors who declined to treat them rather than the vagueness of the state’s abortion ban. So where does that leave the debate about medical exceptions?

Ollstein: So anti-abortion groups’ response to a lot of the challenges to these abortion bans and stories about women in medical emergencies who are getting denied care and suffering real harm as a result, their response has been that there’s nothing wrong with the law. The law is perfectly clear, and that doctors are either accidentally or intentionally misinterpreting the law for political reasons. Meanwhile, doctors say it’s not clear at all. It’s not clear how honestly close to dead someone has to be in order to receive an abortion.

Rovner: And it’s not just in Texas. This is true in a bunch of states, right? The doctors don’t know …

Ollstein: In many states.

Rovner: … right? …

Ollstein: Exactly.

Rovner: … when they can intervene.

Ollstein: Right. And so I think the upcoming Supreme Court ruling on EMTALA [Emergency Medical Treatment and Active Labor Law], which we’ve talked about, could give some indication either way of what doctors are and are not able to do, but that won’t really resolve it either. There is still so much gray area. And so patients and doctors are going to state courts to plead for clarity. They’re going to their legislatures to plead for clarity. And they’re going to state medical boards, including in Texas, to plead for clarity. And so far, they have not gotten any.

Most legislatures have been unwilling to revisit their bans and clarify or expand the exceptions even as these stories play out on the ground of doctors who say, “I know that providing an abortion for this patient is the right thing medically and ethically to do, but I’m so afraid of being hit with criminal charges that I put the patient on a plane out of state instead.” Yeah, it’s just really tough.

And so what we wrote about it is we keep talking about doctors being torn between conflicting state and federal law, and that’s absolutely true, but what we dug into is that the state law just looms so much larger than the federal laws. So when you’re weighing, should I maybe violate EMTALA or should I maybe violate my state’s ban, they’re not going to want to violate their state’s ban because that means jail time, that means losing their license, that means having their freedom and their livelihood taken away.

Whereas an EMTALA violation may or may not mean a fine somewhere down the road. The enforcement has not been as aggressive at the federal level from the Biden administration as a lot of doctors would like it to be. And so, in that environment, they’re really deferring to the state law, and that means some people are not getting care that they maybe need.

Rovner: I say in the meantime, we had yet another jury just last week about a woman who had a miscarriage and could not get a D&C [dilation and curettage procedure] basically. When she went in there was no fetal heartbeat, but she ended up miscarrying at home and almost dying. She was sent away, I believe, from three different facilities. This continues to happen because doctors are concerned about when it is appropriate for them to intervene. And they seem, you’re right, to be leaning towards the “let’s not get in trouble with the state” law, so let’s wait to provide care as long as we think we can.

Well, moving on, we have two stories this week about efforts to treat post-traumatic stress disorder, particularly in military veterans. On Tuesday, an FDA advisory committee recommended against approval of the psychedelic MDMA, better known as ecstasy, for the treatment of PTSD. My understanding is that the panel didn’t reject the idea outright that this could be helpful, only that there isn’t enough evidence yet to approve it. Was I reading that right? Rachel, you guys covered this pretty closely.

Cohrs Zhang: Yes. Yeah, my colleagues did cover this. Certainly I think what’s a discouraging sign, I don’t think there’s any way around it, for some of these companies that are looking at psychedelics and trying to figure out some sort of approval pathway for conditions like PTSD.

One of my colleagues, Meghana Keshavan, she chatted with a dozen companies yesterday and they were trying to put a positive spin on it, that having some opinion or some discussion of a treatment like this by the advisory committee could lay out more clear standards for what companies would have to present in order to get something approved. So I think obviously they have a vested interest in spinning this positively.

But it is a very innovative space and certainly was a short-term setback. But it certainly isn’t a long-term issue if some of these companies are able to present stronger evidence or better trial design. I think there were some questions about whether trial participants actually could figure out whether they were placebo or not, which if you’re taking psychedelic drugs, yeah, that’s kind of a challenge in terms of trial design.

So I think there are some interesting questions, and I am confident that this’ll be something the FDA and industry is going to have to figure out in a space that’s new like this.

Rovner: Yeah, it’s been interesting to follow. Well, in something that does seem to help, one of the first controlled studies of service dogs to treat PTSD has found that man’s best friend can be a therapist as well. Those veterans who got specially trained dogs showed much more improvement in their symptoms than those who were on the doggy wait list as determined by professionals who didn’t know who had the dogs and who didn’t. So pet therapy for the win here?

Raman: I mean, this is the biggest study of this kind that we’ve had so far, and it seems promising. I think one thing will be interesting is if there’s more research, if this would change policy down the line for the VA [Department of Veterans Affairs] or other agencies to be able to get these kinds of service dogs in the hands of more vets.

Rovner: Yeah, I know there’s a huge demand for these kinds of service dogs. I know a lot of people who basically have started training service dogs for veterans. Obviously they were able to do this study because there was a long wait list. They were able to look at people who were waiting but hadn’t gotten a dog yet. So at least in the short term, possibly some help for some people.

Finally this week, in a segment I’m calling “Misery Loves Company,” it’s not just the U.S. where big health systems are getting cyberhacked. Across the pond, quoting here from the BBC, major hospitals in London have declared a critical incident after a cyberattack led to operations being canceled and emergency patients being diverted elsewhere. This sounds painfully familiar.

Maybe we need an international cybercrime fighting agency. Is there one? Is there at least, do we know, is there a task force working on this? Obviously the bigger, more centralized your health care system, the bigger problem this becomes, as we saw with Change Healthcare belonging to United[Healthcare], and this is now … I guess it’s a contractor that works for the NHS [National Health Service]. You can see the potential for really bad stuff here.

Cohrs Zhang: That’s a good question about some international standards, Julie, but I think what we have seen is Sen. Ron Wyden, who leads the Senate Finance Committee, did write to HHS [Department of Health and Human Services] this week and asked HHS to add to multiple-factor authentication as a condition of participation for some of these facilities to try to institute standards that way.

And again, I think there are questions about how much HHS can actually do, but I think it’s a signal that Congress might not want to do anything or think they can do anything if they’re asking the administration to do something here. But we’re still in the very early stages of systems viewing this as worthy of investment and just education about some of the best practices here.

Yeah, certainly it’s going to be a business opportunity for some consulting firms to help these hospitals increase their cybersecurity measures and certainly will be a global market if we see these attacks continue in other places, too.

Rovner: Maybe our health records will be as protected as our Spotify accounts. It would apparently be a step forward. All right, well, that is the news for this week. Now we will play my “Bill of the Month” interview with Bram Sable-Smith, and then we will come back and do our extra credits.

I am pleased to welcome back to the podcast my KFF Health News colleague Bram Sable-Smith, who reported and wrote the latest KFF Health News-NPR “Bill of the Month” about a free cruise that turned out to be anything but. Welcome back to the podcast, Bram.

Bram Sable-Smith: Thanks for having me.

Rovner: So tell us about this month’s patient, who he is, and what happened to him. This is one of the wilder Bills of the Month, I think.

Sable-Smith: Right. So his name is Vincent Wasney. He lives in Saginaw, Michigan. Never been on an airplane before, neither had his [fiancée], Sarah. But when they bought their first house in 2019, their Realtor, as a gift, gifted them tickets for a cruise. My Realtor gave me a tote bag. So, what a Realtor, first of all! What an incredible gift.

Rovner: My Realtor gave me a wine opener, which I do still use.

Sable-Smith: If it sailed to the Caribbean, it’d be equivalent. So their cruise got delayed because of the pandemic, but they set sail in December 2022. And they were having a great time. One of the highlights of their trip was they went to this private island called CocoCay for Royal Caribbean guests, and it included an excursion to go swimming with pigs.

Rovner: Wild pigs, right?

Sable-Smith: Wild pigs, a big fancy water park, all kinds of food. They were having a great time. But it’s also on that island that Vincent started feeling off. And so in the past, Vincent has had seizures. About 10 years earlier, he had had a few seizures. They decided he was probably epileptic, and he was on medicine for a while. He went off the medicine because they were worried about liver damage, and he’d been relatively seizure-free for a long time. It’d been a long time since he’d had a seizure.

But when he was on that island having a great time, it’s when he started to feel off. And when they got back on the cruise ship for the last full day of the cruise, he had a seizure in his room. And he was taken down to the medical center on the cruise ship and he was observed. He was given fluids for a while, and then sent back to his room, where he had a second seizure. Once again, went down to the medical center on the ship, where he had a third seizure. It was time to get him off the boat. He needed to get onto land and go to a hospital. And so they were close enough to land that they were able to do the evacuation by boat instead of having to do something like a helicopter to do a medevac that way. And so a rescue boat came to the ship. He was lowered off the ship. He was in a stretcher and it was lowered down to the rescue boat by a rope.

His fiancée, Sarah, climbed down a rope ladder to get into the boat as well to go with them to land. And then he was taken to land in an ambulance ride to the hospital, et cetera. But, before they were allowed to disembark, they were given their bill and told “It’s time to pay this. You have to pay this bill.”

Rovner: And how much was it?

Sable-Smith: So the bill for the medical services was $2,500. This was a free cruise. They had budgeted to pay for internet, $150 for internet. They had budgeted to pay for their alcoholic drinks. They had budgeted to pay for their tips. So they had saved up a few hundred dollars, which is what they thought would be their bill at the end of this cruise. Now, that completely exploded into this $2,500 bill just for medical expenses alone.

And as they’re waiting to evacuate the ship, they’re like, “We can’t pay this. We don’t have this money.” So that led to some negotiations. They ended up basically taking all the money out of their bank accounts, including their mortgage payment. They maxed out Vincent’s credit card, but they were still $1,000 short. And they later learned once they were on land that Vincent’s credit card had been overdrafted by $1,000 to cover that additional expense.

Rovner: So it turns out that he was uninsured at the time, and we’ll talk about that in a minute. But even if he had had insurance, the cruise ship wasn’t going to let him off the boat until he paid in full, even though it was an emergency? Did I read that right?

Sable-Smith: That’s certainly the feeling that they had at the time. When Vincent was short the $1,000, eventually they were let off the ship, but they did end up, as we said, getting that credit card overdrafted. But I think what’s important to note here is that even though he was uninsured at the time, even if he had had insurance, and even if he had had travel insurance, which he also did not have at the time, which we can talk about, he still would’ve been required to pay upfront and then submit the receipts later to try to get reimbursed for the payments.

And that’s because on the cruise’s website, they explain that they do not accept “land-based health insurance plans” when they’re on the vessel.

Rovner: In fact, as you mentioned, a lot of health insurance doesn’t cover care on a cruise ship or, in fact, anywhere outside the United States. So lots of people buy travel insurance in case they have a medical emergency. Why didn’t they?

Sable-Smith: So travel insurance is often purchased when you purchase the tickets. You’ll buy a ticket to the cruise and then it will prompt you, say, “Hey, do you want some travel insurance to protect you while you’re on this ship?” And that’s the way that most people are buying travel insurance. Well, remember, this cruise was a gift from their realtors, so they never bought the ticket. So they never got that prompting to say, “Hey, time to buy some travel insurance to protect yourself on the trip.”

And again, these were inexperienced travelers. They’d never been on an airplane before. The furthest either one of them had been from Michigan was Vincent went to Washington, D.C., one time on a school trip. And so they didn’t really know what travel insurance was. They knew it existed. But as Vincent explained, he said, “I thought this was for lost luggage and trip cancellations. I didn’t realize that this was something for medical expenses you might incur when you’re out at sea.”

Rovner: And it’s really both. I mean, it is for lost luggage and cancellation, right?

Sable-Smith: And it is for lost luggage and cancellation. Yeah, that’s right.

Rovner: So what eventually happened to Vincent and what eventually happened to the bill?

Sable-Smith: Well, once he got taken to the hospital, he got an additional bill, or actually several additional bills, one from the hospital, two from a couple doctors who saw him at the hospital who billed separately, and also one from the ambulance services. As we know, he had already drained his bank account and maxed out his credit card and had it overdrafted to cover the expenses on the ship. So he was working on paying those off. And then for the additional bills he incurred on land, he had set up payment plans, really small ones, $25, $50 a month, but going to four separate entities.

He actually missed a couple payments on his bill to the hospital, and that ended up getting sent to collections. Again, none of these are charging interest, but these are still quite some burdens. And so he was paying them off bit by bit by bit. He set up a GoFundMe campaign, which is something that a lot of people end up doing who never expect to have to cover these kinds of emergency expenses, or reach out publicly for help like that. And they got quite a bit of help from family and friends. Including, Vincent picked up Frisbee golf during the pandemic, and he’s made quite a lot of good friends that way. And that community really came through for them as well. So with those GoFundMe payments, they were able to make their house payment. It was helpful with some of these bills that they had lingering leftover from the cruise.

Rovner: So what’s the takeaway here, other than that nothing that seems free is ever really free?

Sable-Smith: Yeah, right. Well, the takeaway is to be informed before you leave about a plan for how are you going to cover medical expenses when you’re going traveling. I think this is something that a lot of people are going to be doing this summer, going on vacations. I’ve got vacations planned. What’s your plan for covering medical expenses? And if you’re leaving the country, if you’re going on a cruise, someplace where your land-based American health insurance might not cover you, you should consider travel insurance.

And when you’re considering travel insurance, they come in all sorts of varieties. So you want to make sure that they’re going to cover your particular cases. So some plans, for example, won’t cover pre-existing conditions. Some plans won’t cover care for risky activities like rock climbing. So you want to know what you’re going to be doing during your trip, and you want to make sure when you’re purchasing travel insurance to find a plan that’s going to cover your particular needs.

Rovner: Very well explained. Bram Sable-Smith, thank you very much.

Sable-Smith: Always a pleasure.

Rovner: And now it’s time for our extra credit segment. That’s when we each recommend a story we read this week we think you should read, too. As always, don’t worry if you miss it. We will post the links on the podcast page at kffhealthnews.org and in our show notes on your phone or other mobile device.  Alice, you’ve gone already. Sandhya, why don’t you go next?

Raman: So my extra credit is “Roanoke’s Requiem,” and it’s an Air Mail from Clara Molot. And this is a really interesting piece. So at least 16 alumni from the classes of 2011 to 2019 of Roanoke have been diagnosed with cancer since 2010, which is a much higher rate when compared to the rate for 20-somethings in the U.S. and 15-times-higher mortality rate. And so the piece does some looking at some of the work that’s being done to uncover why this is happening.

Rovner: It’s quite a scary story. Rachel?

Cohrs Zhang: Yes. So the story I chose, it was co-published by ProPublica in Mississippi Today. The headline is “This Mississippi Hospital Transfers Some Patients to Jail to Await Mental Health Treatment,” by Isabelle Taft. And I mean, truly such a harrowing story of … obviously we know that there’s capacity issues with mental health treatment, but the idea that patients would be involuntarily committed, go to a hospital, and then be transferred to a jail having committed no crime, having no recourse.

I mean, some of these detentions happened. It was like two months long where these patients who are already suffering are then thrown out of their comfortable environments into jail as they awaited county facilities to open up spots for them. And I think the story also did a good job of pointing out that other jurisdictions had found other solutions to this other than placing suffering people in jail. So yeah, it just felt like it was a really great classic example of investigative journalism that’ll have an impact.

Rovner: Local investigative journalism — not just investigative journalism — which is really rare, yet it was a really good piece. Well, my extra credit this week is from Jessica Valenti, who writes a super-helpful newsletter called Abortion, Every Day. Usually it’s an aggregation of stories from around the country, but this week she also has her own exclusive [“EXCLUSIVE: Health Data Breach at America’s Largest Crisis Pregnancy Org,”] about how Heartbeat International, which runs the nation’s largest network of crisis pregnancy centers, is collecting and sharing private health data, including due dates, dates of last menstrual periods, addresses, and even family living arrangements.

Isn’t this a violation of HIPAA, you may ask? Well, probably not, because HIPAA only applies to health care providers and insurers and the vast majority of crisis pregnancy centers don’t deliver medical care. You don’t need a medical license to give a pregnancy test or even do an ultrasound. Among other things, personal health data has been used for training sales staff, and until recently was readily available to anyone on the web without password protection. It’s a pretty eye-opening story.

All right, that is our show. As always, if you enjoy the podcast, you can subscribe wherever you get your podcasts. We’d appreciate it if you left us a review; that helps other people find us, too. Special thanks as always to our technical guru, Francis Ying, and our fill-in editor this week, Stephanie Stapleton. As always, you can email us your comments or questions. We’re at whatthehealth@kff.org, or you can still find me at X, I’m at @jrovner. Sandhya?

Raman: @SandhyaWrites.

Rovner: Alice?

Ollstein: @AliceOllstein.

Rovner: Rachel?

Cohrs Zhang: @rachelcohrs.

Rovner: We will be back in your feed next week. Until then, be healthy.

Credits

Francis Ying
Audio producer

Stephanie Stapleton
Editor

To hear all our podcasts, click here.

And subscribe to KFF Health News’ “What the Health?” on Spotify, Apple Podcasts, Pocket Casts, or wherever you listen to podcasts.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

USE OUR CONTENT

This story can be republished for free (details).

This is said to be the first time that a student from the northeastern state has topped the MBBS entrance exam, reports ANI.

The National Testing Agency (NTA) recently announced the NEET 2024 results in which a record-breaking 67 candidates have topped the MBBS entrance exam scoring a remarkable percentage. The candidates achieved a flawless score of 720, placing them as joint top performers. Among these exceptional scorers, 53 are male and 14 are female. The highest percentile attained by these individuals, who hold the first rank in the All India Ranking (AIR), is an impressive 99.997129.

According to the scorecard of the qualified candidates for the National Eligibility cum Entrance Test (NEET), Rajasthan has the highest number of candidates in the top 67 with 11 candidates, followed by Tamil Nadu with 8 candidates and Maharashtra with 7 candidates.

Among the top 67, a male candidate from Maharashtra named Ved Sunilkumar Shende emerged as the Super topper in the NEET 2024 with a perfect score of 720 and a percentage of 99.997129.

Also read- NEET 2024 Results: Here Are The 100 Toppers, Check List

The remaining 66 candidates who have topped the MBBS entrance exam include Syed Aarifin Yusuf M from Tamil Nadu, Mridul Manya Anand from Delhi, Ayush Naugraiya from Uttar Pradesh, Mazin Mansoor from Bihar, Rupayan Mandal from West Bengal, Akshat Pangaria from Uttarakhand, Shaurya Goyal from Punjab, Tathagat Awatar from Bihar, Chand Mallik from Tripura, Prachita from Rajasthan, Shailaja S from Tamil Nadu, Saurav from Rajasthan, Divyansh from Delhi, Gunmay Garg from Punjab, Aadarsh Singh Moyal from Rajasthan, Aditya Kumar Panda from Tamil Nadu, Arghyadeep Dutta from West Bengal, Sriram P from Tamil Nadu, Isha Kothari from Rajasthan, Kasturi Sandeep Chowdary from Andhra Pradesh, Shashank Sharma from Rajasthan, Shubhan Sengupta from Maharashtra.

Saksham Agrawal from West Bengal, Aryan Sharma from Himachal Pradesh, Kahkasha Parween from Jharkhand, Devadarshan R Nair from Kerala, Gattu Bhanuteja Sai from Andhra Pradesh, Umayma Malbari from Maharashtra, Kalyan V from Karnataka, Sujoy Dutta from Delhi, Shyam Jhanwar from Rajasthan, Aryan Yadav from Uttar Pradesh, Manav Priyadarshi from Jharkhand, Palansha Agarwal from Maharashtra, Rajaneesh P from Tamil Nadu, Dhruv Garg from Rajasthan, Krishnamurti Pankaj Shiwal from Maharashtra, Sreenand Sharmil from Kerala, Ved Patel from Gujarat, Sam Shreyas Joseph from Karnataka, Jayathi Poorvaja M from Tamil Nadu, Mane Neha Kuldeep from Maharashtra, Hritik Raj from Bihar, Kriti Sharma from Gujarat, Taijas Singh from Chandigarh, Arjun Kishore from Karnataka, Rohith R from Tamil Nadu, Abhishek V J from Kerala, Sabareesan S from Tamil Nadu, Darsh Paghdar from Gujarat, Shikhin Goyal from Punjab, Amina Arif Kadiwala from Maharashtra.

Devesh Joshi from Rajasthan, Rishabh Shah from Gujarat, Poreddy Pavan Kumar Reddy from Andhra Pradesh, Abhinav Sunil Prasad from Kerala, Samit Kumar Saini from Rajasthan, Iram Quazi from Rajasthan, Vadlapudi Mukhesh Chowdary from Andhra Pradesh, Abhinav Kisna from Bihar, Khushboo from Haryana, Krish from Haryana, Lakshay from Delhi, Anjali from Haryana, Jahnvee from Rajasthan, Prateek from Haryana.

Medical Dialogues team recently reported that 56.4 per cent of the candidates have qualified for the exam, which was conducted on May 5 at centres 571 cities in India and 14 international locations. A record 24.06 lakh candidates had registered for NEET this year. The passing percentage is almost the same as last year at 56.2 per cent.

Among those who have qualified the country's biggest entrance exam for admission to MBBS and BDS courses at the undergraduate level, 5,47,036 are male, 7,69,222 are female and 10 are transgender persons, the NTA said.

The examination was conducted in 13 languages -- Assamese, Bengali, English, Gujarati, Hindi, Kannada, Malayalam, Marathi, Odia, Punjabi, Tamil, Telugu, and Urdu.

NEET-UG is the qualifying entrance exam for admission to Bachelor of Medicine and Bachelor of Surgery (MBBS), Bachelor of Dental Surgery (BDS), Bachelor of Ayurveda, Medicine and Surgery (BAMS), Bachelor of Siddha Medicine and Surgery (BSMS), Bachelor of Unani Medicine and Surgery (BUMS), and Bachelor of Homeopathic Medicine and Surgery (BHMS) and BSc (H) Nursing courses.

There are more than 80,000 MBBS seats in over 540 medical colleges in the country. Of the 13,16,268 qualified candidates, 3,33,932 were from the unreserved category, 6,18,890 from the OBC category, 1,78,738 from SC, 68,479 from ST, and 1,16,229 from the EWS category. Besides, 4,120 candidates from the Persons with Disabilities category have also qualified the exam.

The exam witnessed an increase in qualifying marks this year. For instance, the qualifying marks range for the unreserved category last year was 720-137, which has increased to 720-164 this year. Similarly, for OBC SC, and ST categories, it has increased from 136-107 last year to 163-129 this year.

Also Read:NEET 2024 Results: AIR 1 to 67 Toppers! What's the Tie-breaking Criteria?

The highest percentile attained by these individuals, who hold the first rank in the All India Ranking (AIR), is an impressive 99.997129.

According to the scorecard of the qualified candidates for the National Eligibility cum Entrance Test (NEET), Rajasthan has the highest number of candidates in the top 67 with 11 candidates, followed by Tamil Nadu with 8 candidates and Maharashtra with 7 candidates.

Among the top 67, a male candidate from Maharashtra named Ved Sunilkumar Shende emerged as the Super topper in the NEET 2024 with a perfect score of 720 and a percentage of 99.997129. 

Also read- NEET 2024 Results: Here Are The 100 Toppers, Check List

The remaining 66 candidates who have topped the MBBS entrance exam include Syed Aarifin Yusuf M from Tamil Nadu, Mridul Manya Anand from Delhi, Ayush Naugraiya from Uttar Pradesh, Mazin Mansoor from Bihar, Rupayan Mandal from West Bengal, Akshat Pangaria from Uttarakhand, Shaurya Goyal from Punjab, Tathagat Awatar from Bihar, Chand Mallik from Tripura, Prachita from Rajasthan, Shailaja S from Tamil Nadu, Saurav from Rajasthan, Divyansh from Delhi, Gunmay Garg from Punjab, Aadarsh Singh Moyal from Rajasthan, Aditya Kumar Panda from Tamil Nadu, Arghyadeep Dutta from West Bengal, Sriram P from Tamil Nadu, Isha Kothari from Rajasthan, Kasturi Sandeep Chowdary from Andhra Pradesh, Shashank Sharma from Rajasthan, Shubhan Sengupta from Maharashtra.

Saksham Agrawal from West Bengal, Aryan Sharma from Himachal Pradesh, Kahkasha Parween from Jharkhand, Devadarshan R Nair from Kerala, Gattu Bhanuteja Sai from Andhra Pradesh, Umayma Malbari from Maharashtra, Kalyan V from Karnataka, Sujoy Dutta from Delhi, Shyam Jhanwar from Rajasthan, Aryan Yadav from Uttar Pradesh, Manav Priyadarshi from Jharkhand, Palansha Agarwal from Maharashtra, Rajaneesh P from Tamil Nadu, Dhruv Garg from Rajasthan, Krishnamurti Pankaj Shiwal from Maharashtra, Sreenand Sharmil from Kerala, Ved Patel from Gujarat, Sam Shreyas Joseph from Karnataka, Jayathi Poorvaja M from Tamil Nadu, Mane Neha Kuldeep from Maharashtra, Hritik Raj from Bihar, Kriti Sharma from Gujarat, Taijas Singh from Chandigarh, Arjun Kishore from Karnataka, Rohith R from Tamil Nadu, Abhishek V J from Kerala, Sabareesan S from Tamil Nadu, Darsh Paghdar from Gujarat, Shikhin Goyal from Punjab, Amina Arif Kadiwala from Maharashtra.

Devesh Joshi from Rajasthan, Rishabh Shah from Gujarat, Poreddy Pavan Kumar Reddy from Andhra Pradesh, Abhinav Sunil Prasad from Kerala, Samit Kumar Saini from Rajasthan, Iram Quazi from Rajasthan, Vadlapudi Mukhesh Chowdary from Andhra Pradesh, Abhinav Kisna from Bihar, Khushboo from Haryana, Krish from Haryana, Lakshay from Delhi, Anjali from Haryana, Jahnvee from Rajasthan, Prateek from Haryana.

Medical Dialogues team recently reported that 56.4 per cent of the candidates have qualified for the exam, which was conducted on May 5 at centres 571 cities in India and 14 international locations. A record 24.06 lakh candidates had registered for NEET this year. The passing percentage is almost the same as last year at 56.2 per cent.

Among those who have qualified the country's biggest entrance exam for admission to MBBS and BDS courses at the undergraduate level, 5,47,036 are male, 7,69,222 are female and 10 are transgender persons, the NTA said.

The examination was conducted in 13 languages -- Assamese, Bengali, English, Gujarati, Hindi, Kannada, Malayalam, Marathi, Odia, Punjabi, Tamil, Telugu, and Urdu.

NEET-UG is the qualifying entrance exam for admission to Bachelor of Medicine and Bachelor of Surgery (MBBS), Bachelor of Dental Surgery (BDS), Bachelor of Ayurveda, Medicine and Surgery (BAMS), Bachelor of Siddha Medicine and Surgery (BSMS), Bachelor of Unani Medicine and Surgery (BUMS), and Bachelor of Homeopathic Medicine and Surgery (BHMS) and BSc (H) Nursing courses.

There are more than 80,000 MBBS seats in over 540 medical colleges in the country. Of the 13,16,268 qualified candidates, 3,33,932 were from the unreserved category, 6,18,890 from the OBC category, 1,78,738 from SC, 68,479 from ST, and 1,16,229 from the EWS category. Besides, 4,120 candidates from the Persons with Disabilities category have also qualified the exam.

The exam witnessed an increase in qualifying marks this year. For instance, the qualifying marks range for the unreserved category last year was 720-137, which has increased to 720-164 this year. Similarly, for OBC SC, and ST categories, it has increased from 136-107 last year to 163-129 this year.

"Sixty-seven candidates scored the same 99.997129 percentile score, therefore, they shared the all-India rank one. The merit list will be prepared using a tie-breaking formula with those getting higher marks or percentile score in Biology will be given preference followed by Chemistry and Physics," a senior NTA official said to PTI.

NTA Tie-Breaking Criteria

Medical Dialogues team on March 2024 had reported that the revised Information Bulletin for the NEET-UG 2024 exam, which was uploaded by NTA on its website, specified that NTA will allot ranks to joint scorers based on their performance - the proportion of incorrect and correct answers in Biology, Chemistry and Physics.

When two or more candidates secure the same score in the NEET exam, their ranks are decided in compliance with the tie-breaking policy. 

Back then, NTA released an Information Bulletin and modified the tie-breaking policy for this year. Introducing lucky draw by computer or IT, the tie-breaking policy released by NTA mentioned that in case two or more candidates obtain equal marks, higher ranks will be given to candidates who obtain higher ranks in Biology, followed by marks in Chemistry, followed by higher marks in Physics, and lastly by draw of lots using computer.

However, NMC has decided to go back to its old method of breaking a tie between the same scorers. As per the revised brochure, which has been uploaded on the NTA portal, after prioritizing the marks in Biology, Chemistry, and Physics, the proportion of incorrect and correct answers attempted in all shall be considered for breaking the tie, followed by the proportion in the individual subjects.

"In case of two or more candidates obtain equal marks/percentile scoresin the NEET (UG) - 2024, the inter-se-merit shall be determined as follows:

a. Candidate obtaining higher marks/percentile score in Biology (Botany & Zoology) in theTest, followed by,

b. Candidate obtaining higher marks/percentile score in Chemistry in the Test, followed by,

c. Candidate obtaining higher marks/percentile score in Physics in the Test, followed by,

d. Candidate with less proportion of the number of attempted incorrect answers and correct answers in all the subjects in the Test,

e. Candidate with less proportion of a number of attempted incorrect answers and correct answers in Biology (Botany & Zoology) in the Test, followed by

f. Candidate with less proportion of a number of attempted incorrect answers and correct answers in Chemistry in the Test, followed by

g. Candidate with less proportion of a number of attempted incorrect answers and correct answers in Physics in the Test, followed by"

Also read- NEET 2024: NTA Revises Tie-Breaking Criteria